therapeuticЮжно-Российский журнал терапевтической практикиSouth Russian Journal of Therapeutic Practice2712-8156РостГМУ10.21886/2712-8156-2020-1-1-38-42therapeutic-6Research ArticleОБЗОРЫREVIEWSНА ПОРОГЕ ИЗМЕНЕНИЙ В ЛЕЧЕНИИ СТАБИЛЬНОЙ ИШЕМИЧЕСКОЙ БОЛЕЗНИ СЕРДЦА: ПЕРВЫЕ ИТОГИ ИССЛЕДОВАНИЯ ISCHEMIAON THE THRESHOLD OF CHANGES IN THE TREATMENT OF STABLE CORONARY HEART DISEASE: FIRST RESULTS OF THE ISCHEMIA TRIALhttps://orcid.org/0000-0003-1510-9204КанорскийС. Г.KanorskiiS. G.
д.м.н., проф., заведующий кафедрой терапии № 2 ФПК И ППС
Краснодар
Dr. Sci. (Med.), Prof.
Krasnodar
kanorskysg@mail.ruФГБОУ ВО «Кубанский государственный медицинский университет» Минздрава РоссииРоссияKuban State Medical UniversityRussian Federation202015052020113842Copyright © Канорский С.Г., 20202020Канорский С.Г.Kanorskii S.G.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.therapeutic-j.ru/jour/article/view/6тематический обзоришемическая болезнь сердцареваскуляризация миокардамедикаментозная терапияthematic reviewcoronary heart diseasemyocardial revascularizationdrug therapyReferencesPatel K.K., Spertus J.A., Chan P.S., Sperry B.W., Thompson R.C., Al Badarin F. et al. Extent of myocardial ischemia on positron emission tomography and survival benefit with early revascularization. Journal of the American College of Cardiology. 2019;74(13):1645-1654. doi: 10.1016/j.jacc.2019.07.055.Patel K.K., Spertus J.A., Chan P.S., Sperry B.W., Thompson R.C., Al Badarin F. et al. Extent of myocardial ischemia on positron emission tomography and survival benefit with early revascularization. Journal of the American College of Cardiology. 2019;74(13):1645-1654. doi: 10.1016/j.jacc.2019.07.055.Weintraub W.S., Hartigan P.M., Mancini G.B.J., Teo K.K., Maron D.J., Spertus J.A. et al. Effect of coronary anatomy and myocardial ischemia on long-term survival in patients with stable ischemic heart disease. Circulation. Cardiovascular quality and outcomes. 2019;12(2):e005079. doi: 10.1161/CIRCOUTCOMES.118.005079.Weintraub W.S., Hartigan P.M., Mancini G.B.J., Teo K.K., Maron D.J., Spertus J.A. et al. Effect of coronary anatomy and myocardial ischemia on long-term survival in patients with stable ischemic heart disease. Circulation. Cardiovascular quality and outcomes. 2019;12(2):e005079. doi: 10.1161/CIRCOUTCOMES.118.005079.Канорский С.Г., Смоленская Н.В. Лечение стабильной ишемической болезни сердца: имеет ли коронарное стентирование превосходство над медикаментозной терапией? Кубанский научный медицинский вестник. 2019;26(1):196-208. Doi: 10.25207/1608-6228-2019-26-1-196-208Knuuti J., Wijns W., Saraste A., Capodanno D., Barbato E., Funck-Brentano C. et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European heart journal. 2020;41(3):407-477. doi: 10.1093/eurheartj/ehz425.Knuuti J., Wijns W., Saraste A., Capodanno D., Barbato E., Funck-Brentano C. et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European heart journal. 2020;41(3):407-477. doi: 10.1093/eurheartj/ehz425.Maron D.J., Hochman J.S., Reynolds H.R., Bangalore S., O’Brien S.M., Boden W.E. et al. Initial Invasive or Conservative Strategy for Stable Coronary Disease. The New England journal of medicine. 2020;382(15):1395-1407. doi: 10.1056/NEJMoa1915922.Maron D.J., Hochman J.S., Reynolds H.R., Bangalore S., O’Brien S.M., Boden W.E. et al. Initial Invasive or Conservative Strategy for Stable Coronary Disease. The New England journal of medicine. 2020;382(15):1395-1407. doi: 10.1056/NEJMoa1915922.Bangalore S., Maron D.J., O’Brien S.M., Fleg J.L., Kretov E.I., Briguori C., et al. Management of Coronary Disease in Patients with Advanced Kidney Disease. The New England journal of medicine. 2020;382(17):1608-1618. doi: 10.1056/NEJMoa1915925.Bangalore S., Maron D.J., O’Brien S.M., Fleg J.L., Kretov E.I., Briguori C., et al. Management of Coronary Disease in Patients with Advanced Kidney Disease. The New England journal of medicine. 2020;382(17):1608-1618. doi: 10.1056/NEJMoa1915925.Spertus J.A., Jones P.G., Maron D.J., Mark D.B., O’Brien S.M., Fleg J.L. et al. Health Status after Invasive or Conservative Care in Coronary and Advanced Kidney Disease. The New England journal of medicine. 2020;382(17):1619-1628. doi: 10.1056/NEJMoa1916374.Spertus J.A., Jones P.G., Maron D.J., Mark D.B., O’Brien S.M., Fleg J.L. et al. Health Status after Invasive or Conservative Care in Coronary and Advanced Kidney Disease. The New England journal of medicine. 2020;382(17):1619-1628. doi: 10.1056/NEJMoa1916374.Boden W.E., O’Rourke R.A., Teo K.K., Hartigan P.M., Maron D.J., Kostuk W.J. et al. Optimal medical therapy with or without PCI for stable coronary disease. The New England journal of medicine. 2007;356(15):1503-1516. DOI: 10.1056/NEJMoa070829.Boden W.E., O’Rourke R.A., Teo K.K., Hartigan P.M., Maron D.J., Kostuk W.J. et al. Optimal medical therapy with or without PCI for stable coronary disease. The New England journal of medicine. 2007;356(15):1503-1516. DOI: 10.1056/NEJMoa070829.Sedlis S.P., Hartigan P.M., Teo K.K., Maron D.J., Spertus J.A., Mancini G.B. et al. Effect of PCI on Long-Term Survival in Patients with Stable Ischemic Heart Disease. The New England journal of medicine. 2015;373(20):1937-1946. doi: 10.1056/NEJMoa1505532.Sedlis S.P., Hartigan P.M., Teo K.K., Maron D.J., Spertus J.A., Mancini G.B. et al. Effect of PCI on Long-Term Survival in Patients with Stable Ischemic Heart Disease. The New England journal of medicine. 2015;373(20):1937-1946. doi: 10.1056/NEJMoa1505532.Maron D.J., Mancini G.B.J., Hartigan P.M., Spertus J.A., Sedlis S.P., Kostuk W.J. et al. Healthy Behavior, Risk Factor Control, and Survival in the COURAGE Trial. Journal of the American College of Cardiology. 2018;72(19):2297-2305. doi: 10.1016/j.jacc.2018.08.2163.Maron D.J., Mancini G.B.J., Hartigan P.M., Spertus J.A., Sedlis S.P., Kostuk W.J. et al. Healthy Behavior, Risk Factor Control, and Survival in the COURAGE Trial. Journal of the American College of Cardiology. 2018;72(19):2297-2305. doi: 10.1016/j.jacc.2018.08.2163.Newman J.D., Alexander K.P., Gu X., O’Brien S.M., Boden W.E., Govindan S.C. et al. Baseline Predictors of Low-Density Lipoprotein Cholesterol and Systolic Blood Pressure Goal Attainment After 1 Year in the ISCHEMIA Trial. Circulation. Cardiovascular quality and outcomes.2019;12(11):e006002. doi: 10.1161/CIRCOUTCOMES.119.006002.Newman J.D., Alexander K.P., Gu X., O’Brien S.M., Boden W.E., Govindan S.C. et al. Baseline Predictors of Low-Density Lipoprotein Cholesterol and Systolic Blood Pressure Goal Attainment After 1 Year in the ISCHEMIA Trial. Circulation. Cardiovascular quality and outcomes.2019;12(11):e006002. doi: 10.1161/CIRCOUTCOMES.119.006002.Al-Lamee R., Thompson D., Dehbi H.M., Sen S., Tang K., Davies J. et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet. 2018;391(10115):31-40. doi: 10.1016/S0140-6736(17)32714-9.Al-Lamee R., Thompson D., Dehbi H.M., Sen S., Tang K., Davies J. et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet. 2018;391(10115):31-40. doi: 10.1016/S0140-6736(17)32714-9.Borden W.B., Spertus J.A., Mushlin A.I., Roe M.T., McCoy L.A., Redberg R.F. Antianginal therapy before percutaneous coronary intervention. Circulation. Cardiovascular interventions. 2013;6(4):436-443. doi: 10.1161/CIRCINTERVENTIONS.112.000215.Borden W.B., Spertus J.A., Mushlin A.I., Roe M.T., McCoy L.A., Redberg R.F. Antianginal therapy before percutaneous coronary intervention. Circulation. Cardiovascular interventions. 2013;6(4):436-443. doi: 10.1161/CIRCINTERVENTIONS.112.000215.Mach F., Baigent C., Catapano A.L., Koskinas K.C., Casula M., Badimon L. et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European heart journal. 2020;41(1):111-188. doi: 10.1093/eurheartj/ehz455.Mach F., Baigent C., Catapano A.L., Koskinas K.C., Casula M., Badimon L. et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European heart journal. 2020;41(1):111-188. doi: 10.1093/eurheartj/ehz455.Mach F., Baigent C., Catapano A.L., Koskinas K.C., Casula M., Badimon L. et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European heart journal. 2020;41(1):111-188. doi: 10.1093/eurheartj/ehz455.
The authors declare that there are no conflicts of interest present.